{
    "nctId": "NCT00917748",
    "briefTitle": "Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)",
    "officialTitle": "A Prospective, Randomised, Double-Blind, Placebo-Controlled Phase III Study of Modafinil to Improve Fatigue and Quality of Life in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Prostatic Neoplasms, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 84,
    "primaryOutcomeMeasure": "Fatigue scores daily assessed using the 11-point (0-10) 0 is the lower score and 10 is the highest. this score is calculated using the MD Anderson Symptom Inventory",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Treatment with q3w (every three weeks) docetaxel-based chemotherapy for metastatic breast or prostate cancer at a minimum dose of 50 mg/m2\n* Completed at least two cycles of chemotherapy and intention to treat the patient with at least two further cycles of docetaxel-based chemotherapy\n* Fatigue \\> or = to 4 on the MD Anderson Symptom Inventory fatigue assessment scale during the previous docetaxel chemotherapy cycle\n* SPHERE somatic (SOMA) subscale score \\> or = to 3\n* Worsening of fatigue after commencement of docetaxel chemotherapy\n* Haemoglobin (Hb)\\> or = to 10 g/dL within two weeks before randomisation\n\nExclusion criteria:\n\n* Unable to complete the MD Anderson Symptom Inventory fatigue assessment scale or Functional Assessment of Chronic Illness Therapy-Fatigue Quality of Life survey\n* Require docetaxel chemotherapy dose reduction to less than 50 mg/m2\n* History of chronic fatigue condition\n* Uncontrolled hypertension (blood pressure \\> or = to 150/90 mm Hg\n* Known hypersensitivity / intolerance to modafinil or any of the excipients\n* Pregnant women\n* Psychological, familial, sociological, or geographical conditions that do not permit treatment or medical follow-up and / or prohibit compliance with the study protocol\n* Any serious concomitant illness that, in the opinion of the Investigator, would preclude a patient from participating in the study\n* Non-English speaking\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}